Ecor1 Capital, Llc Buys 74,125 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 74,125 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were purchased at an average price of $13.39 per share, with a total value of $992,533.75. Following the acquisition, the director now owns 15,485,203 shares of the company’s stock, valued at approximately $207,346,868.17. This represents a 0.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc purchased 39,029 shares of Zymeworks stock. The stock was acquired at an average cost of $14.01 per share, for a total transaction of $546,796.29.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were bought at an average cost of $13.13 per share, with a total value of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were bought at an average cost of $14.07 per share, for a total transaction of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was bought at an average cost of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were purchased at an average cost of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The shares were purchased at an average cost of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The stock was purchased at an average cost of $14.38 per share, with a total value of $240,030.96.

Zymeworks Price Performance

Shares of NYSE ZYME opened at $13.99 on Friday. The stock has a market capitalization of $963.63 million, a PE ratio of -9.33 and a beta of 1.10. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70. The business’s fifty day moving average price is $14.36 and its 200-day moving average price is $12.58.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business had revenue of $16.00 million for the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company’s revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.41) earnings per share. As a group, equities analysts expect that Zymeworks Inc. will post -1.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZYME. Ritholtz Wealth Management boosted its holdings in shares of Zymeworks by 6.1% in the fourth quarter. Ritholtz Wealth Management now owns 74,466 shares of the company’s stock worth $1,090,000 after acquiring an additional 4,297 shares during the period. Assenagon Asset Management S.A. boosted its stake in Zymeworks by 93.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock worth $9,403,000 after purchasing an additional 311,107 shares during the period. Barclays PLC grew its holdings in Zymeworks by 476.3% during the 3rd quarter. Barclays PLC now owns 154,384 shares of the company’s stock valued at $1,937,000 after buying an additional 127,595 shares in the last quarter. Jane Street Group LLC increased its position in shares of Zymeworks by 27.3% during the third quarter. Jane Street Group LLC now owns 80,326 shares of the company’s stock valued at $1,008,000 after buying an additional 17,205 shares during the period. Finally, State Street Corp lifted its holdings in shares of Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after buying an additional 67,401 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Citigroup boosted their target price on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Wells Fargo & Company boosted their price objective on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 target price on shares of Zymeworks in a research report on Friday, November 22nd. Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $10.00 to $25.00 in a report on Thursday, November 7th. Finally, Stifel Nicolaus raised their price objective on shares of Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zymeworks presently has a consensus rating of “Moderate Buy” and an average target price of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.